Abstract
AbstractA surprisingly clear picture of the allosteric mechanism connecting G protein-coupled receptor agonists with G protein binding—and back – is revealed by a puzzle of thirty novel 3D structures of the hydroxycarboxylic acid receptor 2 (HCAR2) in complex with eight different orthosteric and a single allosteric agonist. HCAR2 is a sensor of β-hydroxybutyrate, niacin and certain anti-inflammatory drugs. Surprisingly, agonists with and without on-target side effects bound very similarly and in a completely occluded orthosteric binding site. Thus, despite the many structures we are still left with a pertinent need to understand the molecular dynamics of this and similar systems.
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Taggart, A. K. et al. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280, 26649–26652 (2005).
2. Tang, H. et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem. Biophys. Res. Commun. 375, 562–565 (2008).
3. Benyó, Z. et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115, 3634–3640 (2005).
4. Lauring, B. et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. science translational medicine. Clin. Trial. 4, 148ra115 (2012).
5. Munk, C. et al. GPCRdb: the G protein-coupled receptor database—an introduction. Br. J. Pharmacol. 173, 2195–2207 (2016).